{"id":47134,"date":"2025-10-28T12:25:06","date_gmt":"2025-10-28T11:25:06","guid":{"rendered":"https:\/\/digidem-bayern.de\/?p=47134"},"modified":"2025-12-10T12:31:22","modified_gmt":"2025-12-10T11:31:22","slug":"entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick","status":"publish","type":"post","link":"https:\/\/digidem-bayern.de\/en\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/","title":{"rendered":"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick"},"content":{"rendered":"<p>Nach Jahrzehnten der stagnierenden Forschung gibt es wieder Bewegung: Neue monoklonale Antik\u00f6rper gegen Amyloid-Ablagerungen wie Lecanemab oder Donanemab greifen erstmals direkt in die Krankheitsmechanismen der Alzheimer Demenz ein. Bisherige Medikamente konnten lediglich die Symptome lindern, aber nicht das Fortschreiten der Krankheit verlangsamen. Wie vielversprechend sind die neuen Medikamente \u2013 und was ist in den kommenden Jahren an weiteren Neurungen zu erwarten? Und wie wird die Sicherheit und die Wirksamkeit neuer Medikamente in klinischen Studien eigentlich gemessen?<\/p>\n\n\n\n<p>In diesem Webinar gibt <strong>Prof. Dr. Peter Sch\u00fcler<\/strong> einen \u00dcberblick \u00fcber den aktuellen Stand der Entwicklung von Medikamenten gegen Demenz. Dabei spricht er sowohl \u00fcber laufende Studien als auch zuk\u00fcnftige M\u00f6glichkeiten und Herausforderungen im Bereich der Arzneimittelentwicklung. Prof. Dr. Peter Sch\u00fcler ist Senior Vice President im Bereich &#8222;Drug Development Solutions, Neurosciences&#8220; bei der globalen\u00a0<em>ICON Clinical Research Germany GmbH<\/em>\u00a0mit Sitz in Langen (Hessen).<em>\u00a0<\/em>Dar\u00fcber hinaus war er Vorsitzender der Deutschen Gesellschaft f\u00fcr Pharmazeutische Medizin e.V. 2023-2025 und ist Mitglied im digiDEM Bayern Scientific Advisory Board.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Webinar: Entwicklung neuer Medikamente gegen Demenz - Stand und Ausblick\" width=\"1223\" height=\"688\" src=\"https:\/\/www.youtube.com\/embed\/JPpgV8HQXHg?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-text-align-center\"><a href=\"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/2025-10-28_digiDEM-Webinar_Nr74.pdf\" data-type=\"link\" data-id=\"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2024\/11\/2024-11-12_digiDEM-Webinar_Nr63_Copyright.pdf\"><strong>Hier gibt es das Webinar als PDF zum\u00a0Download<\/strong>.<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-stackable-columns stk-block-columns stk-block stk-1abb464\" data-block-id=\"1abb464\"><div class=\"stk-row stk-inner-blocks stk-block-content stk-content-align stk-1abb464-column\">\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-38a7c84\" data-v=\"4\" data-block-id=\"38a7c84\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-38a7c84-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-38a7c84-inner-blocks\">\n<div class=\"wp-block-uagb-team uagb-team__image-position-above uagb-team__align-center uagb-team__stack-tablet uagb-block-df5b540b\"><div class=\"uagb-team__content\"><img decoding=\"async\" class=\"uagb-team__image-crop-circle\" src=\"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2022\/11\/FWE_NEU_Quadrat.jpg\" alt=\"Florian Weidinger\" height=\"120\" width=\"120\" loading=\"lazy\"\/><h3 class=\"uagb-team__title\">Florian Weidinger, M. Sc.<\/h3><span class=\"uagb-team__prefix\">Wissenschaftlicher Mitarbeiter <\/span><p class=\"uagb-team__desc\">Moderation<\/p><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-stackable-column stk-block-column stk-column stk-block stk-3aae72b\" data-v=\"4\" data-block-id=\"3aae72b\"><div class=\"stk-column-wrapper stk-block-column__content stk-container stk-3aae72b-container stk--no-background stk--no-padding\"><div class=\"stk-block-content stk-inner-blocks stk-3aae72b-inner-blocks\">\n<div class=\"wp-block-uagb-team uagb-team__image-position-above uagb-team__align-center uagb-team__stack-tablet uagb-block-7e64a8eb\"><div class=\"uagb-team__content\"><img decoding=\"async\" class=\"uagb-team__image-crop-circle\" src=\"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2022\/11\/AKE_NEU_Qudarat.jpg\" alt=\"\" height=\"120\" width=\"120\" loading=\"lazy\"\/><h3 class=\"uagb-team__title\">Anne Keefer, M. Sc.<\/h3><span class=\"uagb-team__prefix\">Wissenschaftliche Mitarbeiterin <\/span><p class=\"uagb-team__desc\">Chatroom und Betreuung<\/p><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Nach Jahrzehnten der stagnierenden Forschung gibt es wieder Bewegung: Neue monoklonale Antik\u00f6rper gegen Amyloid-Ablagerungen wie Lecanemab oder Donanemab greifen erstmals direkt in die Krankheitsmechanismen der Alzheimer Demenz ein. Bisherige Medikamente konnten lediglich die Symptome lindern, aber nicht das Fortschreiten der Krankheit verlangsamen. Wie vielversprechend sind die neuen Medikamente \u2013 und &hellip;<\/p>","protected":false},"author":7,"featured_media":46060,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"qubely_global_settings":"true","qubely_interactions":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[123],"tags":[13,1710,12,38,14,55,1838,1769,400,1113,1837,1768],"class_list":["post-47134","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciene-watch-live-archiv","tag-alzheimer","tag-aufmerksamkeit","tag-demenz-2","tag-demenzregister","tag-digidem","tag-digitales-demenzregister-bayern","tag-fresenius-universitaet-wiesbaden","tag-icon","tag-kognitive-faehigkeiten","tag-medical-valley-emn-e-v","tag-medikamente-gegen-demenz","tag-peter-schueler"],"qubely_featured_image_url":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"portraits":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-540x320.jpg",540,320,true],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-768x511.jpg",768,511,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-526x350.jpg",526,350,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-734x350.jpg",734,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x300.jpg",520,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false]},"qubely_author":{"display_name":"Anne Keefer","author_link":"https:\/\/digidem-bayern.de\/en\/author\/ag-webinar\/"},"qubely_comment":0,"qubely_category":"<a href=\"https:\/\/digidem-bayern.de\/en\/category\/sciene-watch-live-archiv\/\" rel=\"category tag\">Sciene Watch Live ARCHIV<\/a>","qubely_excerpt":"Nach Jahrzehnten der stagnierenden Forschung gibt es wieder Bewegung: Neue monoklonale Antik\u00f6rper gegen Amyloid-Ablagerungen wie Lecanemab oder Donanemab greifen erstmals direkt in die Krankheitsmechanismen der Alzheimer Demenz ein. Bisherige Medikamente konnten lediglich die Symptome lindern, aber nicht das Fortschreiten der Krankheit verlangsamen. Wie vielversprechend sind die neuen Medikamente \u2013 und &hellip;","featured_image_urls_v2":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-768x511.jpg",768,511,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-526x350.jpg",526,350,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-734x350.jpg",734,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x300.jpg",520,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false]},"post_excerpt_stackable_v2":"<p>Nach Jahrzehnten der stagnierenden Forschung gibt es wieder Bewegung: Neue monoklonale Antik\u00f6rper gegen Amyloid-Ablagerungen wie Lecanemab oder Donanemab greifen erstmals direkt in die Krankheitsmechanismen der Alzheimer Demenz ein. Bisherige Medikamente konnten lediglich die Symptome lindern, aber nicht das Fortschreiten der Krankheit verlangsamen. Wie vielversprechend sind die neuen Medikamente \u2013 und was ist in den kommenden Jahren an weiteren Neurungen zu erwarten? Und wie wird die Sicherheit und die Wirksamkeit neuer Medikamente in klinischen Studien eigentlich gemessen? In diesem Webinar gibt Prof. Dr. Peter Sch\u00fcler einen \u00dcberblick \u00fcber den aktuellen Stand der Entwicklung von Medikamenten gegen Demenz. Dabei spricht er sowohl&hellip;<\/p>\n","category_list_v2":"<a href=\"https:\/\/digidem-bayern.de\/en\/category\/sciene-watch-live-archiv\/\" rel=\"category tag\">Sciene Watch Live ARCHIV<\/a>","author_info_v2":{"name":"Anne Keefer","url":"https:\/\/digidem-bayern.de\/en\/author\/ag-webinar\/"},"comments_num_v2":"0 comments","yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick - digiDEM Bayern<\/title>\n<meta name=\"description\" content=\"Im Webinar &quot;digiDEM Bayern Science Watch LIVE&quot; behandeln Wissenschaftler ein Thema aus der Demenzforschung und stehen live f\u00fcr Fragen zur Verf\u00fcgung.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/digidem-bayern.de\/en\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick - digiDEM Bayern\" \/>\n<meta property=\"og:description\" content=\"Im Webinar &quot;digiDEM Bayern Science Watch LIVE&quot; behandeln Wissenschaftler ein Thema aus der Demenzforschung und stehen live f\u00fcr Fragen zur Verf\u00fcgung.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/digidem-bayern.de\/en\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/\" \/>\n<meta property=\"og:site_name\" content=\"digiDEM Bayern\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/digiDEMBayern\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-28T11:25:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-10T11:31:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"666\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anne Keefer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anne Keefer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/\"},\"author\":{\"name\":\"Anne Keefer\",\"@id\":\"\\\/#\\\/schema\\\/person\\\/0e8781e0653d1a8e57ca55bd2c3cb01f\"},\"headline\":\"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick\",\"datePublished\":\"2025-10-28T11:25:06+00:00\",\"dateModified\":\"2025-12-10T11:31:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/\"},\"wordCount\":207,\"commentCount\":0,\"publisher\":{\"@id\":\"\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/shutterstock_2499290699-webinar-Schueler.jpg\",\"keywords\":[\"Alzheimer\",\"Aufmerksamkeit\",\"Demenz\",\"Demenzregister\",\"digidem\",\"Digitales Demenzregister Bayern\",\"Fresenius Universit\u00e4t Wiesbaden\",\"ICON\",\"Kognitive F\u00e4higkeiten\",\"Medical Valley EMN e.V.\",\"Medikamente gegen Demenz\",\"Peter Sch\u00fcler\"],\"articleSection\":[\"Sciene Watch Live ARCHIV\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/\",\"name\":\"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick - digiDEM Bayern\",\"isPartOf\":{\"@id\":\"\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/shutterstock_2499290699-webinar-Schueler.jpg\",\"datePublished\":\"2025-10-28T11:25:06+00:00\",\"dateModified\":\"2025-12-10T11:31:22+00:00\",\"description\":\"Im Webinar \\\"digiDEM Bayern Science Watch LIVE\\\" behandeln Wissenschaftler ein Thema aus der Demenzforschung und stehen live f\u00fcr Fragen zur Verf\u00fcgung.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/#primaryimage\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/shutterstock_2499290699-webinar-Schueler.jpg\",\"contentUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/shutterstock_2499290699-webinar-Schueler.jpg\",\"width\":1000,\"height\":666,\"caption\":\"Wie vielversprechend sind die neuen Medikamente \u2013 und was ist in den kommenden Jahren an weiteren Neurungen zu erwarten?\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/digidem-bayern.de\\\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/digidem-bayern.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick\"}]},{\"@type\":\"WebSite\",\"@id\":\"\\\/#website\",\"url\":\"\\\/\",\"name\":\"digiDEM Bayern\",\"description\":\"Das digitale Demenzregister Bayern erforscht und verbessert die Angebotsstuktur f\u00fcr Menschen mit Demenz und deren Angeh\u00f6rige\",\"publisher\":{\"@id\":\"\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\\\/#organization\",\"name\":\"digiDEM Bayern\",\"url\":\"\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png\",\"contentUrl\":\"https:\\\/\\\/digidem-bayern.de\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png\",\"width\":612,\"height\":357,\"caption\":\"digiDEM Bayern\"},\"image\":{\"@id\":\"\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/digiDEMBayern\\\/\",\"https:\\\/\\\/x.com\\\/digidem_bayern\",\"https:\\\/\\\/www.instagram.com\\\/digidem.bayern\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/digidem-bayern\\\/\"]},{\"@type\":\"Person\",\"@id\":\"\\\/#\\\/schema\\\/person\\\/0e8781e0653d1a8e57ca55bd2c3cb01f\",\"name\":\"Anne Keefer\",\"url\":\"https:\\\/\\\/digidem-bayern.de\\\/en\\\/author\\\/ag-webinar\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick - digiDEM Bayern","description":"Im Webinar \"digiDEM Bayern Science Watch LIVE\" behandeln Wissenschaftler ein Thema aus der Demenzforschung und stehen live f\u00fcr Fragen zur Verf\u00fcgung.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/digidem-bayern.de\/en\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/","og_locale":"en_US","og_type":"article","og_title":"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick - digiDEM Bayern","og_description":"Im Webinar \"digiDEM Bayern Science Watch LIVE\" behandeln Wissenschaftler ein Thema aus der Demenzforschung und stehen live f\u00fcr Fragen zur Verf\u00fcgung.","og_url":"https:\/\/digidem-bayern.de\/en\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/","og_site_name":"digiDEM Bayern","article_publisher":"https:\/\/www.facebook.com\/digiDEMBayern\/","article_published_time":"2025-10-28T11:25:06+00:00","article_modified_time":"2025-12-10T11:31:22+00:00","og_image":[{"width":1000,"height":666,"url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg","type":"image\/jpeg"}],"author":"Anne Keefer","twitter_misc":{"Written by":"Anne Keefer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/#article","isPartOf":{"@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/"},"author":{"name":"Anne Keefer","@id":"\/#\/schema\/person\/0e8781e0653d1a8e57ca55bd2c3cb01f"},"headline":"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick","datePublished":"2025-10-28T11:25:06+00:00","dateModified":"2025-12-10T11:31:22+00:00","mainEntityOfPage":{"@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/"},"wordCount":207,"commentCount":0,"publisher":{"@id":"\/#organization"},"image":{"@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/#primaryimage"},"thumbnailUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg","keywords":["Alzheimer","Aufmerksamkeit","Demenz","Demenzregister","digidem","Digitales Demenzregister Bayern","Fresenius Universit\u00e4t Wiesbaden","ICON","Kognitive F\u00e4higkeiten","Medical Valley EMN e.V.","Medikamente gegen Demenz","Peter Sch\u00fcler"],"articleSection":["Sciene Watch Live ARCHIV"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/","url":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/","name":"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick - digiDEM Bayern","isPartOf":{"@id":"\/#website"},"primaryImageOfPage":{"@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/#primaryimage"},"image":{"@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/#primaryimage"},"thumbnailUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg","datePublished":"2025-10-28T11:25:06+00:00","dateModified":"2025-12-10T11:31:22+00:00","description":"Im Webinar \"digiDEM Bayern Science Watch LIVE\" behandeln Wissenschaftler ein Thema aus der Demenzforschung und stehen live f\u00fcr Fragen zur Verf\u00fcgung.","breadcrumb":{"@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/#primaryimage","url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg","contentUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg","width":1000,"height":666,"caption":"Wie vielversprechend sind die neuen Medikamente \u2013 und was ist in den kommenden Jahren an weiteren Neurungen zu erwarten?"},{"@type":"BreadcrumbList","@id":"https:\/\/digidem-bayern.de\/entwicklung-neuer-medikamente-gegen-demenzen-stand-und-ausblick\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/digidem-bayern.de\/"},{"@type":"ListItem","position":2,"name":"Entwicklung neuer Medikamente gegen Demenzen \u2013 Stand und Ausblick"}]},{"@type":"WebSite","@id":"\/#website","url":"\/","name":"digiDEM Bavaria","description":"The digital dementia register in Bavaria researches and improves the structure of services for people with dementia and their relatives","publisher":{"@id":"\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/#organization","name":"digiDEM Bavaria","url":"\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/#\/schema\/logo\/image\/","url":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2022\/03\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png","contentUrl":"https:\/\/digidem-bayern.de\/wp-content\/uploads\/2022\/03\/cropped-Allgemeines_digiDEMLOGO-removebg-preview.png","width":612,"height":357,"caption":"digiDEM Bayern"},"image":{"@id":"\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/digiDEMBayern\/","https:\/\/x.com\/digidem_bayern","https:\/\/www.instagram.com\/digidem.bayern","https:\/\/www.linkedin.com\/company\/digidem-bayern\/"]},{"@type":"Person","@id":"\/#\/schema\/person\/0e8781e0653d1a8e57ca55bd2c3cb01f","name":"Anne Keefer","url":"https:\/\/digidem-bayern.de\/en\/author\/ag-webinar\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-80x80.jpg",80,80,true],"medium":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-300x200.jpg",300,200,true],"medium_large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-768x511.jpg",768,511,true],"large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"1536x1536":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"2048x2048":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"trp-custom-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",18,12,false],"qubely_landscape":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"qubely_portrait":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-540x320.jpg",540,320,true],"qubely_thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-140x100.jpg",140,100,true],"post-thumbnail":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-526x350.jpg",526,350,true],"kahuna-featured":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-734x350.jpg",734,350,true],"kahuna-featured-lp":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"kahuna-featured-half":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-800x350.jpg",800,350,true],"kahuna-featured-third":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-512x350.jpg",512,350,true],"kahuna-lpbox-1":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x300.jpg",520,300,true],"kahuna-lpbox-2":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"demand-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"dddkt-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"ddiqc-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"ddtl-language-flag":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-36x36.jpg",36,36,true],"mailpoet_newsletter_max":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false],"kahuna-lpbox-3":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-520x350.jpg",520,350,true],"kahuna-featured-square":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler-512x512.jpg",512,512,true],"kahuna-featured-square-large":["https:\/\/digidem-bayern.de\/wp-content\/uploads\/2025\/10\/shutterstock_2499290699-webinar-Schueler.jpg",1000,666,false]},"uagb_author_info":{"display_name":"Anne Keefer","author_link":"https:\/\/digidem-bayern.de\/en\/author\/ag-webinar\/"},"uagb_comment_info":0,"uagb_excerpt":"Nach Jahrzehnten der stagnierenden Forschung gibt es wieder Bewegung: Neue monoklonale Antik\u00f6rper gegen Amyloid-Ablagerungen wie Lecanemab oder Donanemab greifen erstmals direkt in die Krankheitsmechanismen der Alzheimer Demenz ein. Bisherige Medikamente konnten lediglich die Symptome lindern, aber nicht das Fortschreiten der Krankheit verlangsamen. Wie vielversprechend sind die neuen Medikamente \u2013 und &hellip;","_links":{"self":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts\/47134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/comments?post=47134"}],"version-history":[{"count":1,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts\/47134\/revisions"}],"predecessor-version":[{"id":47135,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/posts\/47134\/revisions\/47135"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/media\/46060"}],"wp:attachment":[{"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/media?parent=47134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/categories?post=47134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digidem-bayern.de\/en\/wp-json\/wp\/v2\/tags?post=47134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}